Specifically, the award will be used to explore the utilization of PET imaging biomarkers to enable measurement of target engagement and pathway activation of the sigma-1 receptor (SIGMAR1) with clinically relevant doses in Parkinson's disease patients, according to Anavex.

The foundation had previously funded a clinical trial that established Anavex 2-73 as a potentially disease-modifying treatment for Parkinson's disease, the company said.